PFE — Pfizer Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapSuper Stock

Annual cashflow statement for Pfizer, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	22,025	31,407	2,158	8,062	7,812
Depreciation
Deferred Taxes
Non-Cash Items	-3,147	1,016	5,868	2,836	4,788
Discontinued Operations
Extraordinary Items
Unusual Items
Other Non-Cash Items
Changes in Working Capital	12,804	-4,456	-2,174	-3,065	-5,354
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	32,580	29,267	8,700	12,744	11,705
Capital Expenditures	-2,711	-3,236	-3,907	-2,909	-2,629
Purchase of Fixed Assets
Other Investing Cash Flow Items	-19,835	-12,547	-28,371	5,561	1,278
Acquisition of Business
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-22,546	-15,783	-32,278	2,652	-1,351
Financing Cash Flow Items	16	-335	-632	-469	-459
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-9,816	-14,834	26,066	-17,140	-10,304
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	159	-1,515	2,448	-1,810	91